The Advanced therapy medicinal products Manufacturing Community
Meet the people behind the community
Dr Angela OsborneeXmoor Pharma Concepts Limited
Angela is the managing director of eXmoor Pharma, a manufacturing consultancy in cell therapies and biopharmaceuticals, which she founded in 2004.
Angela’s specific role on eXmoor’s projects includes programme management and early definition of GMP manufacturing requirements for new cell therapy products.
Angela is a member of the BIA’s Cell Therapy Industry Group advisory committee, advisor to the HealthTech & Medicines KTN on Regenerative Medicine strategy, lecturer on the UCL MBI programme and is passionate about developing cell therapies for the benefit of patients and the UK economy.
Emily is a scientist working in cell and gene therapy and is External Strategy Manager, Gene Therapy at the GSK Rare Diseases Unit.
She has a background in Chemistry and Biochemical Engineering, looking at engineering growth substrates for pluripotent stem cell bioprocessing during her PhD (University College London). As a Director of the LRMN, Emily previously represented the network on a number of UK and EU consortium projects looking at cell therapy technologies and business modelling.
She sits on the International Society for Cell Therapy’s Executive Committee as Global Treasurer and is a Scientific Advisor at Proteus Venture Partners and a member of the UK BIA’s Cell Therapy Advisory Committee, as well as a member of the American, European, and British Societies for Gene and Cell Therapy.
Lucy is the Lead Biopharmaceutical Engineer at the National Biologics Manufacturing Centre.
Prior to joining the NMBC Lucy was a lecturer in Biopharmaceutical Engineering in the Department of Chemical Engineering and Advanced Materials at Newcastle University. Previously Lucy was a Research Associate in Newcastle University Business School where she worked with Profs Lyddiatt and Whitaker to understand the route to widespread adoption and process industrialisation of advanced therapies. Lucy holds visiting posts at Monash University, Melbourne and Newcastle University.
Chris Mason is a co-founder and Chief Scientific Officer at AvroBio Inc., an ex vivo gene therapy company based in Cambridge, Massachusetts. Since 2008, he has been Professor of Regenerative Medicine Bioprocessing in the Advanced Centre for Biochemical Engineering, University College London working on the clinical translation and commercialization of cell and gene therapies.
He has a multidisciplinary track record, spanning R&D, clinical medicine, bioprocessing, regulation, healthcare economics, reimbursement and business.
Mark LowdellRoyal Free Hospital London
Professor Mark Lowdell PhD FRCPath FRSB is the Professor of Cell & Tissue Therapy at University College London and Director of the Centre for Cell, Gene & Tissue Therapeutics / Honorary Consultant Immunologist at Royal Free Hospital London.
He is a qualified diagnostic immunopathologist as well as holding MHRA Qualified Person status for the release of ATMPs for clinical trials and is the current Vice President (Europe & Middle East) of the International Society for Cell Therapy.
Dr Stephen WardCell Therapy Catapult
Stephen was appointed Chief Operating Officer of the Cell Therapy Catapult in January 2013. He brings over 20 years of biological medicine research, development, and manufacturing experience to the organisation.
Stephen enjoys bringing cutting edge technologies to patients, by developing commercially viable products and has developed and validated scaleable, commercial manufacturing processes for cell based medicinal products, vaccines, and recombinant biologicals using Quality by Design principles.
Whilst the UK is excellent in scientific development of cell therapies, robust manufacturing processes, essential to establishing industry, now need to be developed.
Developing best practice in cell therapy manufacturing
ATMP Manufacturing Communityamc
By building a critical mass we can share best practice and act as a voice to suppliers, regulators and industry to establish robust cell therapy manufacture.
Our vision is that the whole ATMP Manufacturing Community is the team. Members are encouraged to attend, speak and facilitate our meetings, as well as being proactive in our online presence.